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Ligation of CD40 on monocytes through its interaction
with CD40 ligand (CD154) present on activated T helper
cells, results in activation of monocyte inflammatory
cytokine synthesis and rescue of monocytes from apoptosis induced through serum deprivation. Both of these
consequences of CD40 stimulation have been shown to
be dependent on the induction of protein tyrosine kinase activity. CD40-mediated activation of protein tyrosine kinase activity and subsequent inflammatory cytokine production are abrogated by treatment of
monocytes with the T helper type 2 cytokines interleukin 4 (IL-4) and interleukin 10 (IL-10). In the current
study we demonstrate that stimulation of monocytes
through CD40 resulted in the phosphorylation and activation of the extracellular signal-regulated kinases 1
and 2 (ERK1/2) mitogen-activated protein kinases,
whereas phosphorylation of mitogen-activated protein
kinases family members p38 and c-Jun N-terminal kinase was not observed in response to this stimuli over
the time course examined. PD98059, an inhibitor of the
upstream activator of ERK1/2, the MAP/ERK kinase
MEK1/2, suppressed IL-1b and tumor necrosis factor-a
production in a dose-dependent fashion. Pretreatment
of monocytes with IL-4 and IL-10 inhibited CD40-mediated activation of ERK1/2 kinase activity when used
individually, and are enhanced in effectiveness when
used in combination. Together, the data demonstrate
that CD40-mediated induction of IL-1b and tumor necrosis factor-a synthesis is dependent on a MEK/ERK pathway which is obstructed by signals generated through
the action of IL-4 and IL-10.

Monocyte activation by T cells, such as occurs in autoimmune inflammatory disease, involves the influence of both cell
contact-dependent as well as cytokine-generated signals (1).
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tor:ligand pair which contributes to contact-dependent signaling between these cell types. Early studies of CD40 focused on
its role in co-stimulation of B cell proliferation and immunoglobulin isotype switching (2), culminating with the finding
that X-linked Hyper-IgM Syndrome, an immunodeficiency
characterized by absence of circulating IgG and IgA and by the
absence of germinal centers, is a result of defects in the gene
encoding CD154 (3, 4). A broader role of CD40 signaling was
revealed through the finding that CD40 is expressed on numerous cell types including, in addition to monocytes, dendritic
cells, fibroblasts, keratinocytes, endothelial cells, and vascular
smooth muscle cells (5–11). Stimulation of these cell types
through CD40 induces cell functions that contribute to inflammatory responses, such as activation of cytokine synthesis and
enhancement of co-stimulatory and adhesion molecule expression (12). In monocytes/macrophages the interaction of CD40
with CD154 has been shown to result in the activation of
inflammatory cytokine production (5, 6) and nitric oxide production (13, 14), as well as rescue from apoptosis (15, 16). The
contribution of CD40 signaling to T cell activation of macrophages was further substantiated by the demonstration that
CD41 T cells from CD154-knockout mice are deficient in their
ability to induce macrophage effector function (14). The finding
that humans (17) and mice (18) with defective CD154 genes
display an increased susceptibility to disseminated infections
by microorganisms usually contained by cell-mediated immune
function also indicates that productive T cell-macrophage interactions depend on the presence of functional CD154.
The role of monocyte/macrophage-derived inflammatory cytokines in inflammatory autoimmune diseases has been well
established (19). Therefore, the demonstration that the CD40CD154 interaction contributes to the ability of T cells to activate monocyte/macrophage inflammatory cytokine synthesis
suggested that this receptor:ligand pair may contribute to the
maintenance and/or exacerbation of autoimmune inflammatory disease. In murine models of autoimmune disease, including collagen-induced arthritis, thyroiditis, and experimental
autoimmune encephalomyelitis, blockade of the CD40-CD154
interaction blocked development of these autoimmune diseases
(20 –22). The role of CD154-CD40 interactions in disease onset
in these cases has been ascribed to the requirement for CD40mediated induction of co-stimulatory molecules necessary for T
cell activation (23, 24). However, current evidence indicates
that the role of the CD154-CD40 interaction goes beyond the
initial contact signaling events. For example, although antiCD154 treatment inhibits the development of experimental
autoimmune encephalomyelitis, it was also shown that antiCD154 treatment of animals after onset of experimental autoimmune encephalomyelitis reduced the extent and severity of
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lesions by more than 50% (22). In addition, obstruction of
inflammatory cytokine signaling can reduce symptoms of ongoing inflammatory disease as shown recently in clinical studies in which blockade of TNF1 responsiveness through treatment with soluble TNF receptor reduced symptoms of
rheumatoid arthritis (25). Clearly, the reduced inflammation
resulting from blockade of CD154-CD40 interactions is due to
the inhibition of a number of crucial outcomes of CD40 signaling, including T cell induction of monocyte/macrophage inflammatory cytokine synthesis.
Previous work from our laboratory has demonstrated that
activation of monocyte inflammatory cytokine synthesis
through the CD154-CD40 interaction is effectively inhibited by
the T helper type 2-derived cytokines IL-4 and IL-10. Numerous studies, in vitro, have shown that IL-4 and IL-10 downregulate monocyte/macrophage inflammatory function in response to stimulation with lipopolysaccharide (LPS) (26 –28).
In vivo studies have demonstrated that these cytokines can
reduce autoimmune inflammatory disease (29 –33) and recently clinical trials involving use of IL-10 as therapy for autoimmune disease have been initiated with success (34, 35).
Our previous in vitro studies suggest that the in vivo effectiveness of these cytokines in autoimmune disease may result, in
part, from their direct effect on monocyte/macrophage activation by T cells mediated through CD40 signaling.
The signaling pathway(s) involved in CD40-mediated induction of monocyte inflammatory cytokine synthesis have not
been fully characterized, nor has the mechanism of IL-4 or
IL-10 inhibition of this process. In earlier studies, we demonstrated that the pathway of monocyte CD40 signaling resulting
in activation of inflammatory cytokine synthesis and rescue
from apoptosis is critically dependent on the generation of PTK
activity and does not show dependence on the activity of the
serine/threonine protein kinase C family (15, 16). IL-4 and
IL-10 inhibited CD40-induced tyrosine phosphorylation of
monocyte cellular proteins, and down-regulated CD40-induced
IL-1b in a synergistic manner (16). In the present study we
have evaluated the role of MAPK family members in the CD40
signaling of inflammatory cytokine production and the influence of IL-4 and IL-10 on MAPK activity. CD40 signaling in
monocytes resulted in the rapid phosphorylation and accompanying activation of ERK1/2, whereas phosphorylation of MAPK
family members p38 and c-Jun N-terminal kinase (JNK), was
not observed. The data herein provide evidence that CD40mediated induction of IL-1b and TNFa synthesis is dependent
on MEK1/2 activity and demonstrate that activation of the
MEK1/2/ERK1/2 pathway is a target for the inhibitory action of
IL-4 and IL-10 in monocytes.
MATERIALS AND METHODS

Control of Endotoxin Contamination—All cell culture reagents used
were either certified as low endotoxin when purchased, or were ensured
low endotoxin as determined by chromogenic limulus assay (BioWhittaker, Walkersville, MD). Stock solutions containing .1 ng/ml (10 endotoxin units/ml) were considered unacceptable. Stock solutions were
diluted in assays such that endotoxin levels did not exceed 1 pg/ml.
Reagents, Antibodies, and Cell Lines—Sodium orthovanadate
(Na3VO4) was acquired from Fisher Scientific, (Pittsburgh, PA). IL-4
and IL-10 were purchased from R&D Systems (Minneapolis, MN). The

1
The abbreviation used are: TNF, tumor necrosis factor; PTK, protein tyrosine kinase; IL, interleukin; ERK1/2, extracelluar signal-regulated kinase 1 and 2; MAPK, mitogen activated protein kinase; MEK,
MAP/ERK kinase; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; R5, RPMI with 5% fetal bovine serum; PAGE, polyacrylamide gel
electrophoresis; TmA, purified plasma membranes from activated
CD41T cells; TmR, purified plasma membranes from resting CD41T
cells; Jak, Janus family kinase; NFkB, nuclear factor kB; SOCS, suppressors of cytokine synthesis.

MEK1/2 inhibitor PD98059 was obtained from New England BioLabs,
Inc. (Beverly, MA). The following mAbs were prepared from culture
supernatants of hybridomas purchased from the American Type Culture Collection (ATCC, Rockville, MD): IgG mouse anti-human IL-1b
(H-6A), IgG mouse anti-human CD3 (OKT-3), IgG mouse anti-human
CD8 (OKT-8), IgG mouse anti-human monocyte (3C10), IgG mouse
anti-human B cell (LYM-1), and IgM mouse anti-human NK cell (hNK1). BioMagTM iron-conjugated goat anti-human IgG and IgM were obtained from PerSeptive Diagnostics, Inc. (Cambridge, MA). IgG mouse
anti-human CD154 mAb was obtained from Genzyme (Cambridge, MA)
and an IgG isotype control mAb was purchased from Pharmingen (San
Diego, CA). Rabbit antibodies recognizing the active, phosphorylated
(Thr183 and Tyr185) form of ERK1/2 were acquired from Promega (Madison, WI) and from New England BioLabs. Rabbit antibodies recognizing phosphorylated p38 (Thr180 and Tyr182) and phosphorylated JNK
(Thr183 and Tyr185) were purchased from New England BioLabs. Horseradish peroxidase-conjugated F(ab9)2 donkey anti-rabbit Ab was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA).
Cell lines used in these studies included 293 (human embryonic
kidney, ATTC), stable transfectants of 293 which express high levels of
CD154 (36), the human T cell leukemia line Jurkat (ATTC), and the
CD1541 sublcone of Jurkat, D1.1 (37). Both D1.1 and the 293-CD154
transfectants were gifts of Dr. Seth Lederman, Columbia University.
Cell lines were maintained in RPMI 1640 (Hyclone, Logan, UT), containing 100 mM HEPES, 50 mg/ml gentamicin, and fetal bovine serum at
5% (henceforth designated as R-5). The 293-CD154 transfectants (created by co-transfection with pcDNA1-CD154 and pRSVneo) were periodically passaged in 200 mg/ml G418 (Life Technologies, Inc.).
Monocyte Isolation and Culture—Blood was collected from normal,
healthy human volunteers and peripheral blood mononuclear cells were
isolated over a Ficoll density gradient (Fico-Lite-LymphoH, Atlanta
Biologicals, Norcross, GA). Peripheral blood mononuclear cells were
plated at a density of 5 3 106 cells/well in 24-well tissue culture plates
or at 5 3 105/well in 96-well plates (Falcon Primaria, Lincoln Park, NJ)
in R5. Monocytes were isolated by plastic adherence for 1 h at 37 °C
after which nonadherent cells were removed by Pasteur pipetting during 2 washes with Dulbecco’s phosphate-buffered saline. For use in
immune complex kinase assays, monocytes were purified from peripheral blood mononuclear cells by counterflow elutriation as described
previously (38).
CD41 T Cell Purification and Activation—CD41 T cells were purified
by negative magnetic panning from elutriation-enriched T cell populations. Cells were incubated in R-5 with mAbs against cell surface
molecules generated from the hybridomas OKT-8 (anti-CD81 T cell),
3C10 (anti-monocyte), LYM-1 (anti-B cell), and hNK-1 (anti-NK cell),
used as culture supernatants at dilutions of 1:10, for 30 min at room
temperature. Cells were then treated with BioMagTM iron-conjugated
antibodies to murine IgG and IgM (PerSeptive Diagnostics, Cambridge,
MA) for 30 min with gentle shaking at 4 °C. Cells were diluted with
Dulbecco’s phosphate-buffered saline in 75-cm2 flasks (Fisher Scientific) and the CD42 populations were removed via 27 megagauss Oerstead magnets (PerSeptive Diagnostics). A sample of the purified population was stained with an fluorescein isothiocyanate-conjugated antiCD4 mAb and analyzed by flow cytometry on a FACSTARTM Plus flow
cytometer (Becton Dickinson, San Jose, CA). Resulting populations
were typically found to be greater than 95% CD41. CD41 T cells were
then rested in R-5 alone, or activated for 6 h in R-5 by incubation with
10 ng/ml phorbol 12-myristate 13-acetate (Sigma) and 0.5 mM ionomycin
(Calbiochem, San Diego, CA). Expression of CD154 on activated, but
not resting, CD41 T cells was then confirmed by flow cytometric
analysis.
T Cell Plasma Membrane Preparation—For the preparation of purified plasma membranes, resting and activated purified CD41 T cells
were resuspended in a hypotonic buffer containing 50 mM Tris-HCl, pH
7.4, 25 mM KCl, 5 mM MgCl2, and 50 mg/ml phenylmethylsulfonyl
fluoride for 30 min on ice. The cells were then homogenized using a
PowerGen 35 homogenizer (Fisher Scientific) until completely disrupted as determined microscopically. Disrupted cells were centrifuged
at 500 3 g for 5 min to remove nuclei, then centrifuged at 95,000 3 g for
30 min using a Ti-50 rotor in a Beckman L5– 65 Ultracentrifuge. Cell
debris was resuspended in 35% (w/v) sucrose/hypotonic buffer then
layered on 73% (w/v) sucrose/hypotonic buffer. Hypotonic buffer was
layered on the 35% sucrose and the samples were centrifuged using a
SW50.1 rotor at 130,000 3 g for 1 h to separate plasma membranes. The
plasma membrane layer (at the 73–35% interface) was collected and
diluted 1:5 with hypotonic buffer, then centrifuged again for 1 h at
130,000 3 g to pellet purified plasma membranes. The membrane
pellets were resuspended in phosphate-buffered saline and total protein
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was determined by microtiter plate protocol of the bicinchoninic acid
protein assay (Pierce, Rockford, IL). The bicinchoninic acid protein
assay was read on a Biotek Instruments microtiter plate reader at 561
nm.
Analysis of IL-1b and TNFa Synthesis—Induction of IL-1b production by monocytes was measured by metabolically labeling the cells
with 50 mCi/ml Tran35S-LabelTM (ICN Radiochemicals, Irvine, CA) in
methionine-deficient RPMI 1640 (Hyclone, Logan, UT). After labeling,
cells were rinsed with Dulbecco’s phosphate-buffered saline and lysed
in cold immunoprecipitation buffer containing 25 mM Tris-HCl, pH 7.4,
1% Triton X-100, 1% deoxycholate, 0.35 M NaCl, 10 mM EDTA, and 50
mg/ml phenylmethylsulfonyl fluoride. IL-1b was immunoprecipitated
from the cell lysates with mouse anti-human IL-1b followed by isolation
with Immobilized rProtein-ATM (Repligen Corp., Cambridge, MA). Precipitates were analyzed by SDS-PAGE in 15% minigels followed by
autoradiography. For analysis of TNFa production stimulated through
CD40, monocytes were plated in 96-well plates in R5 and co-incubated
with 293, 293-CD154 transfectants, Jurkat, or D1.1 cells. Supernatants
were harvested after an 18-h incubation and assayed by enzyme-linked
immunosorbant assay using R&D system’s QuantikineTM TNFa enzyme-linked immunosorbant assay system.
Western Blot Analysis of MAPK Phosphorylation—Prior to stimulation, monocytes were pretreated with 100 mM Na3VO4 for 20 min to
negate protein tyrosine phosphatase effects on tyrosine-phosphorylated
cellular proteins during stimulation. After monocyte treatment/stimulation in 24-well plates, cells were lysed in 50 ml of boiling treatment
buffer (125 mM Tris, pH 6.8, 2% SDS, 20% glycerol, 1% b-mercaptoethanol, and 0.003% bromphenol blue) containing 200 mM phenylmethylsulfonyl fluoride and 1 mM sodium orthovanadate. Samples were resolved by SDS-PAGE in 15% minigels. Proteins were transferred to
BioBlot-NC nitrocellulose membranes (Corning Costar Corp., Kennebunk, ME) using a Trans-BlotTM SD Semi-Dry Electrophoretic Transfer
Cell (Bio-Rad). Antibody-bound proteins were detected using an enhanced chemiluminescence ECLTM Western blotting analysis system
(Amersham Corp.) and the membranes were exposed to Kodak X-Omat
LS x-ray film.
Immune Complex Kinase Assay—Elutriation purified monocytes
were plated in 6-well plates at 3 3 106 well. After a 30-min stimulation
period the cells were harvested in a lysis buffer containing 20 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM
sodium pyrophosphate, 1 mM b-glycerol phosphate, 1 mM Na3VO4, 20
mg/ml phenylmethylsulfonyl fluoride, and 1 mg/ml leupeptin. Active
ERK1/2 was immunoprecipitated from the cell lysates with polyclonal
rabbit anti-phospho-ERK1/2 followed by incubation with Immobilized
rProtein-ATM. Immune complexes were suspended in a kinase buffer
containing 25 mM Tris, pH 7.5, 5 mM glycerol phosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2, and 200 mM ATP to which 2 mg
of Elk1 fusion protein (New England BioLabs) was added for a 30-min
incubation. The samples were analyzed by SDS-PAGE and Western blot
(as described above) using phospho-specific Elk1 antibody (New England BioLabs) as a probe, followed by horseradish peroxidase-conjugated F(ab9)2 goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories) for detection using the ECLTM Western blotting analysis
system. X-ray films were analyzed by scanning densitometry using the
UN-SCAN-IT-gel automated digitizing system, Silk Scientific Corp.,
Orem, UT.
RESULTS

T Cell Activation of Monocytes through CD40 Results in
Activation of the ERK1/2 MAPKs—Experiments were designed
to evaluate the role of MAPKs in T cell activation of monocytes
through CD40 signaling. Stimulus was provided by plasma
membranes purified from CD41 T cells which had been activated for 6 h (a time point at which CD154 expression was
optimal) as well as by co-culture of monocytes with CD154
transfectants, or the CD1541 Jurkat T cell variant, D1.1 (36,
37). Controls included use of purified plasma membranes from
resting (CD1542) CD41 T cells, and the CD1542 293 and
Jurkat parent cell lines. Plasma membrane preparations were
titrated for activity based on membrane protein concentrations.
In the experiments presented herein membranes were used at
10 mg of protein/ml. In these, and in previous experiments (5,
15, 16), we have demonstrated that the activation of monocytes
induced through co-incubation with plasma membranes purified from 6-h activated CD41 T cells is inhibited by addition of
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FIG. 1. CD40 signaling results in activation of ERK1/2. A, top
panel, monocytes were left as unstimulated (control) or treated for 30
min with TmR, TmA, or TmA 1 antibody, as indicated. Cell lysates
were analyzed on SDS-PAGE followed by Western blotting using a
polyclonal antibody directed against the dually phosphorylated ERK1
(44 kDa) ERK2 (42 kDa). Bottom panel, the Western blot (above) was
stripped and re-probed with anti-b-actin mAb as a loading control. B,
immune complex kinase assay of CD40-mediated ERK activation.
Monocytes were either left as unstimulated (control) or stimulated with
TmA as indicated. After a 30-min incubation, monocyte lysates were
immunoprecipitated with anti-phospho-ERK1/2 antibody. The pelleted
immunoprecipitates were incubated with an Elk1-glutathione S-transferase fusion protein as a substrate and phosphorylation of Elk1 was
visualized by Western blot using antibody specific for phosphorylated
Elk1. Panels A and B are representative of two separate experiments
which yielded similar results.

anti-CD154 antibodies (as is activation by CD154 transfectants
and the D1.1 cell line), indicating that the primary activating
component of this reagent is the CD40 ligand, CD154.
To evaluate the ability of CD40 stimulation to activate
MAPKs, monocytes were treated with plasma membranes purified from either activated (CD1541) or resting (CD1542)
CD41 T cells, designated TmA and TmR, respectively. After a
30-min incubation period, cell lysates were harvested and analyzed for MAPK activation by Western blot using antibodies
specific for the phosphorylated (active) forms of ERK1/2, p38,
and JNK. In the first set of experiments the influence of CD40
signaling on ERK1/2 phosphorylation was evaluated. Treatment of monocytes with TmA, but not TmR (each at 10 mg/ml),
resulted in the phosphorylation of ERK1 (44 kDa) and ERK2
(42 kDa) and pretreatment of TmA with anti-CD154 mAb, but
not with an isotype-matched control mAb, greatly reduced CD40dependent ERK1/2 activation (Fig. 1A). Although the samples
evaluated represent lysates generated from an equal number of
cells, the blot was stripped and re-probed with anti-b-actin as a
loading control ensuring that discrepancies in gel loading or
electroblotting had not occurred. b-Actin levels were equivalent
between groups (Fig. 1A, lower panel).
The induction of ERK1/2 phosphorylation would be expected
to be accompanied by enhanced kinase activity. The induction
of ERK1/2 kinase activity via CD40 signaling was assessed
using an immune complex kinase assay. ERK1/2 was immunoprecipitated from control and TmA-treated monocyte lysates
using anti-phospho-ERK1/2 antibodies. The resulting immunoprecipitates were incubated with an Elk1-GST fusion protein
and phosphorylation of Elk1 was assayed by Western blot
using a phospho-specific Elk1 antibody. Induction of ERK1/2
kinase activity through CD40 stimulation was confirmed by the
phosphorylation of Elk1 substrate apparent in the TmA, but
not in the control monocyte lysates (Fig. 1B).
The ability of TmA to induce MAPK phosphorylation was
evaluated over a 2-h time period postactivation. ERK1/2 phosphorylation was evident at 10 min, and declined at 2 h (Fig. 2A,
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FIG. 2. Analysis of MAPK phosphorylation in response to CD40
signaling. A, analysis of ERK1/2 phosphorylation. Monocytes were
either left unstimulated, or stimulated with LPS for 30 min, or TmA for
10, 30, 60, and 120 min as indicated. After stimulation, the lysates were
harvested and analyzed by Western blot with antibodies recognizing
the phosphorylated form of ERK1/2 (top panel) or antibodies recognizing total ERK1/2 (bottom panel). B, analysis of p38 and JNK phosphorylation. Monocytes stimulated as in A, above, were lysed and the
lysates analyzed by Western blot with antibodies recognizing the phosphorylated forms of p38 and JNK, as indicated. The data shown in
panels A and B are representative of two separate experiments.

top panel). Probing the blot with antibody recognizing both
phosphorylated and nonphosphorylated forms of ERK present
revealed that the differences observed were not due to differences in the level of ERK1/2 protein, or artifacts of gel loading
(Fig. 2, bottom panel). Although LPS stimulation resulted in
the phosphorylation of both p38 and JNK (p46), as previously
reported (39, 40), treatment of monocytes with TmA over the
same 2-h time period examined in Fig. 2A, did not induce or
enhance p38 or JNK phosphorylation (Fig. 2B). Probing with
anti-phospho-p38 revealed a low level of phosphorylated protein present in unstimulated monocytes. LPS enhanced the
level of phosphorylation of p38, whereas TmA stimulation had
no influence of p38 phosphorylation at the time points tested.
Phospho-JNK was undetectable in control or TmA-stimulated
cells. Lysates of anisomycin-treated glioma cells and UVtreated 293 cells (New England BioLabs) were used as positive
controls for anti-phospho-p38 and anti-phospho-JNK reactive
proteins, respectively (not shown).
MEK Activity Is Required for CD40 Signaling of IL-1b and
TNFa Synthesis in Monocytes—We next addressed the question as to whether the activation of ERK1/2 has functional
significance in terms of induction of inflammatory cytokine
synthesis. The role of CD40-mediated activation of ERK1/2 in
the induction of inflammatory cytokine production was explored via upstream blockade of the ERK1/2 pathway. Activation of ERK1/2 is catalyzed by the dual specificity kinase
MEK1/2, which, itself, is activated through serine phosphorylation catalyzed by Raf family kinases (41). Use of the specific
MEK1/2 inhibitor, PD98059, which prevents Raf-mediated activation of MEK1/2 (42), allowed us to evaluate the role of the
MEK/ERK pathway in CD40-mediated induction of IL-1b and
TNFa synthesis. PD98059 effectively inhibited ERK1/2 phosphorylation in monocytes as assayed by Western blot and had
no adverse effects on cell viability in a concentration range of
1–100 mM tested, even during prolonged periods of treatment,
as confirmed by examining total de novo protein synthesis after
metabolic labeling of cells with [35S]methionine (not shown). To
determine the role of MEK activity in CD40 induction of IL-1b
synthesis monocytes were pretreated with PD98059 for 1 h

FIG. 3. CD40 signaling of IL-1b and TNFa synthesis in monocytes requires MEK1/2 activity. A, CD40-mediated IL-1b synthesis
in the presence of PD98059. Monocytes were preincubated for 1 h in the
presence or absence of PD98059, then stimulated with TmA for 4 h in
the presence of [35S]methionine for metabolic labeling of proteins. Cell
lysates were harvested and immunoprecipitated with monoclonal antiIL-1b antibody. Lane 1, lysates from unstimulated monocytes; lane 2,
TmA stimulated monocytes; lane 3, TmA 1 1 mM PD98059; lane 4, TmA
1 10 mM PD98059; lane 5, TmA 1 30 mM PD98059. The data shown is
representative of two separate experiments. B, CD40-mediated TNFa
synthesis in the presence of PD98059. Monocytes were plated in 96-well
tissue culture plates to which 293 control cells or 293-CD154 transfectants were added at 104 cell/well. 293-CD154 cells were either incubated with untreated monocytes or with monocytes pretreated with
PD98059 at 5, 10, 30, or 60 mM as indicated. After an 18-h incubation
the cell supernatants were assayed by TNFa enzyme-linked immunosorbant assay. Two independent experiments are displayed which
are representative of four separate experiments yielding similar results. C, as a specificity control, monocytes were incubated with 293CD154 or 293-CD154 1 1 mg/ml anti-CD154 as shown. The data in B
and C are presented as the mean of triplicate determinations of supernatant TNFa content 1 S.D.

prior to CD40 stimulation with TmA. IL-1b induction was
analyzed by radiolabeling of monocytes during stimulus and
immunoprecipitation of radiolabeled protein with monoclonal
anti-IL-1b antibody. Pretreatment of monocytes with PD98059
effectively blocked CD40-mediated IL-1b synthesis induced by
TmA in a dose-dependent manner, as assayed by immunoprecipitation of radiolabeled protein synthesized over a 4-h period
of stimulation with TmA (Fig. 3A).
The influence of PD98059 on monocyte TNFa synthesis in
response to CD40 stimulation was analyzed by enzyme-linked
immunosorbant assay of monocyte supernatants. Monocytes
were stimulated by addition of CD154-transfected 293 cells
(293-CD154) in the presence or absence of PD98059, and supernatants were collected for analysis at 18 h. Controls con-
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FIG. 4. Preincubation of monocytes with IL-4 and IL-10 inhibits ERK1/2 activation and does not affect ERK expression. Top
panel, monocytes preincubated with IL-4 and IL-10 at 5, 10, and 50
ng/ml, as indicated, were analyzed by Western blot for level of ERK1/2
phosphorylation using anti-phospho-ERK1/2 antibodies. Middle panel,
the film shown in the top panel was scanned and the digitized image
analyzed for band density. The histogram represents density (total
pixels minus background 3 1023) of the ERK2 bands. Bottom panel, the
Western blot probed with anti-phospho-ERK1/2 (top panel) was
stripped and re-probed with an anti-ERK1/2 which recognizes both
active and inactive forms of the kinase.

sisted of supernatants from monocytes stimulated with the 293
parent line. Monocyte TNFa synthesis was induced by interaction with the CD154 transfectants, but not by co-culture with
the control 293 population, and was suppressed by addition of
PD98059 in a dose-dependent manner (Fig. 3B). Similar results
were obtained using TmA or the CD1541 D1.1 Jurkat subclone
as stimulus. In both cases PD98059 inhibited TNFa induction
in a similar fashion to that shown in Fig. 3B. The level of
blockade of TNFa synthesis varied dependent on the overall
level of response, with a robust response requiring higher levels of the compound for inhibition than experiments in which a
lower overall response was observed (due to donor variation),
as shown in the two experiments selected for display (Fig. 3B).
Complete inhibition of CD40-induced TNFa synthesis was observed at 60 mM, a concentration that effectively inhibits activation of both MEK1 and MEK2 (42). The specificity of the role
of CD40-CD154 interactions in the induction of TNFa in these
experiments was confirmed by the ability of anti-CD154 to
abrogate monocyte responses to this stimuli (Fig. 3C). Isotype
control antibodies had no effect on CD40-mediated induction of
TNFa synthesis (not shown). These data indicate that MEK
activation of ERK1/2 is a critical element of the CD40-mediated
signaling pathway leading to IL-1b and TNFa synthesis in
monocytes.
IL-4 and IL-10 Inhibit CD40-mediated Activation of the
MEK/ERK Pathway—In previous work IL-4 and IL-10 were
found to inhibit CD40-induced activation of PTK activity and
the subsequent synthesis of inflammatory cytokines (16).
Given the results above indicating a role of MEK and ERK
activation in this pathway, we asked if IL-4 and IL-10 acted by
interference of the signaling cascade leading to ERK1/2 activation. To address this question, monocytes were pretreated for
an 18-h period with IL-4 or IL-10 prior to TmA stimulation and
the cell lysates were assayed for phosphorylation of ERK1/2.
ERK1/2 activation was decreased in a dose-dependent manner
with both IL-4 and IL-10 (Fig. 4). Quantification by scanning
densitometry indicated that a dose of 50 ng/ml IL-4 resulted in
79% decrease in the level of phosphorylation observed over
background in response to TmA. A 90% decrease was observed
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FIG. 5. IL-4 and IL-10 inhibit CD40-mediated ERK1/2 phosphorylation. Top panel, monocyte lysates were analyzed by Western blot
for level of ERK1/2 phosphorylation using anti-phospho-ERK1/2 antibodies. Lane 1, TmR treated; lane 2, TmA treated; lane 3, TmA 1 10
ng/ml IL-4; lane 4, TmA 1 10 ng/ml IL-10; lane 5, TmA 1 IL-4 and IL-10
at 5 ng/ml each. The data shown are representative of four separate
experiments. Middle panel, the film shown (top panel) was scanned and
the digitized image analyzed for band density. The histogram represents density (total pixels minus background 3 1023) of the ERK2
bands. Bottom panel, the Western blot probed with anti-phosphoERK1/2 (top panel) was stripped and re-probed with anti-b-actin.

with treatment of IL-10 at 50 ng/ml. Neither of these cytokines
affected the level of expression of ERK’s during this time period
as shown by Western blots of the same samples, re-probed with
an antibody reactive with total ERK1/2, which show equivalent
levels of ERK1/2 regardless of treatment (Fig. 4, bottom panel).
In our earlier work, we demonstrated that IL-4 and IL-10 could
act synergistically in the down-regulation of IL-1b synthesis
and PTK activity (16). Likewise, activation of ERK1/2 was
reduced further with a combination of IL-4 and IL-10 than with
either cytokine alone (Fig. 5, lane 5). In the experiment shown,
IL-4 and IL-10 at 10 ng/ml reduced TmA-induced ERK activation by approximately 50%, based on scanning densitometry
(Fig. 5, middle panel), whereas the combination of IL-4 and
IL-10 at 5 ng/ml each reduced phosphorylation of ERK1/2 resulted in a 90% reduction in the level of phosphorylation seen
in response to TmA (Fig. 5, lane 5). Re-probing with anti-bactin as a loading control ensured that the differences observed
were not due to artifacts of gel loading or electroblotting (Fig. 5,
bottom panel).
IL-4 and IL-10 inhibition of ERK1/2 kinase activity was
demonstrated by assay of ERK1/2 kinase activity in anti-phospho-ERK1/2 immunoprecipitates of monocytes treated with
TmA in the presence of IL-4 and IL-10. Monocytes were stimulated with TmA as above in the presence of IL-4 or IL-10
individually at 10 ng/ml, or the combination of the two cytokines at 5 ng/ml each. IL-4 and IL-10 inhibited ERK1/2 kinase
activity as measured by phosphorylation of the Elk1 substrate
when used independently, and displayed synergy when combined (Fig. 6A). Scanning densitometry indicated that IL-4
reduced ERK1/2 kinase activity as measured by phosphorylation of Elk1 by approximately 70% of that induced by TmA,
whereas a 90% reduction in kinase activity was observed with
IL-10 treatment (Fig. 6, lanes 4 and 5, respectively). The combination of IL-4 and IL-10 reduced ERK1/2 kinase activity to
the background value (Fig. 6, lane 6).
DISCUSSION

Over the past several years data has accumulated demonstrating that CD40-CD154 interactions contribute to normal
cell-mediated responses as well as to chronic inflammatory
disease (12). In the case of autoimmune inflammatory disease,
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FIG. 6. IL-4 and IL-10 inhibit CD40-mediated activation of ERK1/2 kinase activity. A, monocytes were either left untreated or
preincubated 18 h with IL-4, IL-10, or a combination of the cytokines. The cells were then left untreated or treated with TmR or TmA. Lane 1,
unstimulated; lane 2, TmA treated; lane 3, TmR treated; lane 4, TmA 1 10 ng/ml IL-4; lane 5, TmA 1 10 ng/ml IL-10; lane 6, TmA 1 IL-4 and IL-10
at 5 ng/ml each. After a 30-min incubation the lysates were immunoprecipitated with anti-phospho-ERK1/2 and ERK1/2 kinase activity was
assessed as in Fig. 1B, using an Elk1 fusion protein substrate. B, the film shown in panel A was scanned and the digitized image analyzed for band
density. The histogram represents density (total pixels minus background 3 1023) of the bands reactive with anti-phospho-Elk1 antibody.

studies thus far suggest a scenario whereby self-reactive
CD1541 T cells activate resting CD401 monocytes/macrophages resulting in production of inflammatory mediators and
prolongation of monocyte lifespan, with the net effect being the
maintenance or aggravation of the inflammatory process. The
signaling pathways activated through CD40 in monocytes have
not been clearly delineated. However, CD40 signaling in B cells
has been reported to involve activation of src family PTKs,
serine/threonine kinases, Jak3, MAPK family members (JNK,
p38, and ERK1/2), and phospholipase-g2 (43– 47). Downstream
events in CD40-mediated signaling in B cells include the activation of transcription factors NFkB (48, 49), NFAT, AP-1 (50),
and STAT6 (51). As is the case for other members of TNF
receptor superfamily, CD40, itself, does not contain cytoplasmic sequences with catalytic activity and has been shown to
employ adapter proteins of the TNF receptor-associated factor
family as a means to mediate intracellular signaling events
(52–54). Signaling through CD40 as well as through TNF receptor stimulation has been shown to initiate TNF receptorassociated factor-mediated activation of MAPK family members. TNF receptor-associated factor 2 has been shown to
mediate JNK activation in response to TNFa (55) and expression of TNF receptor-associated factor 6 was found to be associated with activation of ERK2 in a co-transfection system
using the 293 human embryonic kidney cell line (56).
Thus far, studies dealing with CD40-mediated responses in
monocytes have established that induction of PTK activity is an
early event in this pathway and is required for both the activation of inflammatory cytokine synthesis as well as rescue
from apoptosis (15, 16). The present study evaluated the potential role of MAPK family members as downstream mediators of CD40 signaling in monocytes. ERK1/2, p38, and JNKs
were all considered as likely candidates as mediators of CD40
signaling in monocytes based on several criteria. For example,
each of the three MAPKs have been implicated in both LPS
activation of monocytes (40, 57), as well as in CD40-mediated
activation of B cells, as mentioned above (58 – 63). In addition,
JNK isoforms and p38 have been shown to mediate signaling
by members of the TNF receptor superfamily (64, 65), of which
CD40 is a member. Studies of MAPK activation in B cell models
have yielded mixed results, which may be a result of the diversity of the source of B cells used in these studies, as well as the
use of various transformed B cell lines. The work presented
herein employed primary human monocytes, exclusively, to
evaluate the role of MAPKs in monocyte responses to ligation of

CD40 with CD154. The stimulus used in these studies, which
included plasma membranes purified from activated (CD1541)
CD41 T cells and CD154 transfectants, allowed for cross-linking of CD40 through interaction with the physiological form of
CD154, which exists in the membrane as heteromultimeric
complexes (66).
Our data demonstrate that CD40 signaling in monocytes
results in rapid phosphorylation and activation of ERK1/2
(Figs. 1 and 2), whereas over the same time period of stimulation, phosphorylation of p38 and JNK was not increased above
background (Fig. 2). As expected, the CD40-mediated phosphorylation of ERK1/2 was accompanied by enhanced kinase activity as shown by immune complex kinase assay of lysates
from CD40-stimulated monocytes (Fig. 1B). Thus far, ERK1/2
is the only characterized substrate of the MAP kinase kinase
MEK1/2. Therefore, the ability of the MEK1/2 inhibitor
PD98059 to abrogate CD40-mediated IL-1b and TNFa production (Fig. 3) ascribes functional significance to ERK1/2 activation in the pathway leading to inflammatory cytokine synthesis. The nature of ERK1/2’s contribution to initiation/
enhancement of TNFa and IL-1b transcriptional control is a
matter of ongoing investigation. Both genes are regulated, in
part, by the action of nuclear factor kB (NFkB) (67, 68) and
nuclear factor IL-6 (69), in addition to other transcription factors, including AP-1(70) and PU.1 (71). Of these, nuclear factor
IL-6 is known to be a direct substrate of ERK1/2 catalytic
activity (72), whereas the activity of AP-1 components are
influenced by ERK1/2 through increased expression of c-Fos as
a downstream result of ERK1/2 phosphorylation of Elk1, rather
than via direct activation (73).
Although p38 and JNK do not appear to be phosphorylated in
response to CD40 stimulation over the 2-h time period evaluated, we have not ruled out the possibility that these MAPKs
may be involved in later signaling events resulting from autocrine IL-1b and/or TNFa stimulation. Although TmA stimulation did not enhance phosphorylation of p38 above background
levels during the 2-h time period examined, in some experiments, addition of the compound SB203580, an inhibitor of p38
activity (74), reduced TNFa production in response to CD40
stimulation over an 18 –24-h period (not shown). The possibility
that this reduction is due to an inhibition of IL-1b autocrine
stimulation, resulting in p38 activation and enhancement of
TNFa production (75, 76), is being investigated.
A goal of this line of research is not only to gain an understanding of the means by which CD40 signaling leads to in-
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flammatory cytokine synthesis in monocytes, but also to determine how this process can be suppressed. To this end we have
evaluated the ability of the anti-inflammatory cytokines IL-4
and IL-10 to modulate CD40 signaling in monocytes. In earlier
studies we demonstrated that both IL-4 and IL-10 inhibited
CD40-induced PTK activity, and dramatically down-regulated
CD40-induced IL-1b production in a synergistic manner. IL-4
and IL-10 did not significantly lower CD40 surface expression
and were effective when added at the same time as stimulus,
indicating a direct effect on the CD40 signaling pathway (16).
The data herein show that both cytokines reduced CD40-induced phosphorylation of ERK1/2 and, in concordance with the
ability of the two cytokines to synergize in down-regulating
cytokine production, the data presented in Fig. 5 suggest that
they may be synergistic in their ability to reduce activation of
ERK1/2, as well, since 5 ng/ml of both cytokines reduced
ERK1/2 phosphorylation to a greater degree than 10 ng/ml of
either cytokine alone. The reduced phosphorylation of ERK1/2
in IL-4- and IL-10-treated monocytes correlated with reduced
kinase activity as measured by immune complex kinase assay
(Fig. 6).
IL-4 and IL-10 appear to act early in the CD40 signal transduction pathway. They reduce overall PTK induction, which we
have shown is a requirement for cytokine synthesis by the
ability of PTK inhibitors to effectively block CD40-activated
cytokine synthesis (16). Not surprisingly, PTK inhibitors block
CD40-mediated activation of ERK1/2 (not shown). Our results
are similar to those obtained in a study of IL-10 effects on LPS
mediated signaling, in which IL-10 was shown to block LPS
activation of PTK activity and the subsequent activation of Ras
and Raf-1 (77). The involvement of ERK1/2 in CD40 signaling
suggests that CD40 also triggers activation of the classical
Ras/Raf-1 pathway and this possibility is being explored.
Both IL-4 and IL-10 signal through receptors which associate with and activate Janus family (Jak) tyrosine kinases upon
ligation. Substrates of Jak’s include the STAT (signal transducers and activators of transcription) family of transcription
factors (78) and IL-10 has been shown to activate STATs 1 and
3 (79) in monocytes/macrophages. STATs are responsible for
the induction of a family of negative regulators of cytokine
signaling termed SOCS (suppressor of cytokine signals) which
act either directly or indirectly to inhibit Jak activity as a
negative feedback mechanism (80). Although, a recent report
presented evidence that CD40 may associate with Jak3 in B
cells (46), CD40-mediated activation of Jaks in monocytes has
not been investigated. If a functional association of Jak kinases
and CD40 exists in monocytes, this would open the possibility
of SOCS modulation of CD40 signaling. However, as mentioned
previously, IL-4 and IL-10 can implement inhibition when
added simultaneously with stimulus (16). Although the inhibitory effect is less dramatic than when the cells are pretreated
with the cytokines, the data do indicate that inhibition can be
achieved through rapid responses to IL-4 and IL-10 signaling
that are less likely to require transcriptionally controlled
events. The data indicate that IL-4 and IL-10 essentially
“undo” the early PTK-initiated signals generated through
CD40 ligation, suggesting that these cytokines may initiate or
enhance tyrosine phosphatase activity, leading to suppression
of CD40 signaling. The synergistic nature of IL-4 and IL-10
inhibition of CD40 signaling implies that these cytokines must
employ divergent mechanisms to impede the MEK/ERK
pathway.
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